The bispecific (anti-EpCAM x anti-CD3) trifunctional antibody Catumaxomab was investigated as monotherapy in a phase I/II study, in which this compound was shown to be relatively safe and possibly effective in gastric, colorectal and pancreatic cancer [138]. Here, EPCAM is linked to pancreatic neoplasm.